Clinical Trial

Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients

Study acronym: FB1006
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a randomized double-blind controlled exploratory clinical study to evaluate the efficacy and safety of FB1006 in the treatment of amyotrophic lateral sclerosis (ALS) patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-06-20; most recent amendment 2023-11-20.
Trial Details
NCT Number NCT05923905
Lead Sponsor Peking University Third Hospital
Conditions Sporadic and Familial Amyotrophic Lateral Sclerosis
Enrollment 64 participants
Start Date 2023-01-18
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2023-11-22